Methods	Multicentre, randomised, double-blind, placebo-controlled, parallel-group. Single dose to treat single attack Medication administered at onset of migraine aura Assessments at 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h after dosing Second unblinded dose of sumatriptan 6 mg available after 2 h for inadequate relief Rescue medication available 2 h after second dose of study medication
Participants	Aged 18 to 65 years, meeting IHS criteria for migraine (1988) with aura. At least 6-month history of migraine (untreated severity ≥ moderate) and at least 50% of attacks with aura Excluded participants with previous use of subcutaneous sumatriptan N = 177 (171 for efficacy, 82 with moderate or severe baseline pain intensity) M 46, F 125 (73%) Mean age 40 years All treated attacks with aura
Interventions	Sumatriptan 6 mg, n = 90 (88 for efficacy, 47 with moderate or severe baseline pain intensity) Placebo, n = 87 (83 for efficacy, 35 with moderate or severe baseline pain intensity)
Outcomes	Headache relief (at 1 h) Adverse events Withdrawals
Notes	Oxford Quality Score: R1, DB2, W1. Total = 4.
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Low risk	Matching placebo
Study size	High risk	Treatment groups <50 participants